Pavla Chomynová1,2,3, Rita Kočárová1,4,5, Filip Kňažek1,6, Michaela Plevková1, Barbora Bláhová1, Karel Valeš1, Viktor Mravčík1,3,7. 1. National Institute of Mental Health, Klecany, Czech Republic. 2. Czech National Monitoring Centre for Drugs and Addiction, Office of the Government of the Czech Republic, Prague, Czech Republic. 3. Department of Addictology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. 4. Faculty of Arts, Charles University, Prague, Czech Republic. 5. Beyond Psychedelics, Prague, Czech Republic. 6. Faculty of Pharmacy, Masaryk University, Brno, Czech Republic. 7. Spolecnost Podane ruce, Brno, Czech Republic.
Abstract
OBJECTIVES: Different psychoactive substances are widely used in today's society. So far limited data are available on the use of psychedelics in the general population. The main aim of this study is to estimate the numbers of users of substances with psychedelic properties (classical psychedelics, cannabis, ecstasy, and ketamine) in the Czech Republic. METHODS: Data from two samples enrolled in representative cross-sectional questionnaire surveys in the Czech adult population in 2016 (n = 2,785) and 2018 (n = 1,665) were analysed. Prevalence rates were extrapolated to estimate numbers of current, i.e., last-year, users of psychedelics, and their socio-demographic profiles were compared with non-users and users of cannabis. RESULTS: An estimated 5-6% of the Czech adult population (350-430 thousand people) used classical psychedelics (LSD, psilocybin mushrooms, ayahuasca) in their lifetime, increasing up to 28-30% when cannabis is included (1.9-2.1 million users). Current use of classical psychedelics reached 0.7-1.9% (50-130 thousand people), and 9-11% (590-750 thousand users) when cannabis was included. Users of psychedelics were more often males, of younger age and single. CONCLUSIONS: No significant socio-demographic differences were found between users of classical psychedelics and recreational cannabis users, however, differences were significant when compared to non-users and users of other illicit drugs. Findings should further serve to inform drug policy and social and healthcare systems in respect to the use of psychedelics.
OBJECTIVES: Different psychoactive substances are widely used in today's society. So far limited data are available on the use of psychedelics in the general population. The main aim of this study is to estimate the numbers of users of substances with psychedelic properties (classical psychedelics, cannabis, ecstasy, and ketamine) in the Czech Republic. METHODS: Data from two samples enrolled in representative cross-sectional questionnaire surveys in the Czech adult population in 2016 (n = 2,785) and 2018 (n = 1,665) were analysed. Prevalence rates were extrapolated to estimate numbers of current, i.e., last-year, users of psychedelics, and their socio-demographic profiles were compared with non-users and users of cannabis. RESULTS: An estimated 5-6% of the Czech adult population (350-430 thousand people) used classical psychedelics (LSD, psilocybin mushrooms, ayahuasca) in their lifetime, increasing up to 28-30% when cannabis is included (1.9-2.1 million users). Current use of classical psychedelics reached 0.7-1.9% (50-130 thousand people), and 9-11% (590-750 thousand users) when cannabis was included. Users of psychedelics were more often males, of younger age and single. CONCLUSIONS: No significant socio-demographic differences were found between users of classical psychedelics and recreational cannabis users, however, differences were significant when compared to non-users and users of other illicit drugs. Findings should further serve to inform drug policy and social and healthcare systems in respect to the use of psychedelics.
Entities:
Keywords:
cannabis; epidemiology; hallucinogens; medical cannabis; psychedelics; substance use
Authors: Peter S Hendricks; Christopher B Thorne; C Brendan Clark; David W Coombs; Matthew W Johnson Journal: J Psychopharmacol Date: 2015-01-13 Impact factor: 4.153
Authors: Melanie J Miller; Juan Albarracin-Jordan; Christine Moore; José M Capriles Journal: Proc Natl Acad Sci U S A Date: 2019-05-06 Impact factor: 11.205
Authors: Henrik Jungaberle; Sascha Thal; Andrea Zeuch; Ansgar Rougemont-Bücking; Maximilian von Heyden; Helena Aicher; Milan Scheidegger Journal: Neuropharmacology Date: 2018-06-30 Impact factor: 5.250